GlassScriptPhysician profile
Neva A Castro
NPI 1386025385
$1,658.96
in general payments reported to CMS, 2019-2025
15 companies · $537 in 2025
The $537 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.44 · 2021: $393 · 2022: $254 · 2023: $130 · 2024: $268 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.86 | 2020-2025 | Rinvoq, Skyrizi |
| Intercept Pharmaceuticals, INC. | $215.35 | 2021-2023 | Ocaliva |
| Boston Scientific Corporation | $155.93 | 2025 | Axios |
| Takeda Pharmaceuticals U.S.A., INC. | $128.94 | 2020-2025 | Gattex, Entyvio, Eohilia |
| Genzyme Corporation | $117.67 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $110.79 | 2021 | |
| Madrigal Pharmaceuticals | $88.69 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $80.82 | 2022-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $57.04 | 2024 | Omvoh |
| Pfizer INC. | $40.70 | 2025 | |
| Phathom Pharmaceuticals, INC. | $34.81 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $30.44 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $24.38 | 2022 | |
| Ardelyx, INC. | $23.46 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.08 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neva Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.